Femasys is trading 5.33% down at $1.42, with no direct catalyst established.
- No clear company-specific announcement was found for October 26, 2026.
- The latest identified company news was an October 20 SandsRx Pharmacy partnership supporting FemaSeed; it does not explain the decline.
- Major indexes are higher, so broad-market weakness does not account for the move; trading volume details were not reliably verified.